Literature DB >> 11122837

New developments in lymphoma clinical trials.

C S Portlock1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11122837     DOI： 10.1007/s11912-000-0087-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


× No keyword cloud information.
  18 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

3.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

4.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

5.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Brice; Y Bastion; E Lepage; N Brousse; C Haïoun; P Moreau; N Straetmans; H Tilly; I Tabah; P Solal-Céligny
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Rituximab in indolent lymphoma: the single-agent pivotal trial.

Authors:  P McLaughlin; F B Hagemeister; A J Grillo-López
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

7.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.

Authors:  A S Freedman; D Neuberg; J G Gribben; P Mauch; R J Soiffer; D C Fisher; K C Anderson; N Andersen; R Schlossman; M Kroon; J Ritz; J Aster; L M Nadler
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

8.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

Authors:  G P Canellos; J R Anderson; K J Propert; N Nissen; M R Cooper; E S Henderson; M R Green; A Gottlieb; B A Peterson
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

9.  Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.

Authors:  N L Bartlett; S A Rosenberg; R T Hoppe; S L Hancock; S J Horning
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

Authors:  P Solal-Céligny; E Lepage; N Brousse; C L Tendler; P Brice; C Haïoun; J Gabarre; B Pignon; G Tertian; R Bouabdallah; J F Rossi; C Doyen; B Coiffier
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.